The first patient has now been enrolled on to the Entheon Biomedical Phase 1 Study of DMT.
On International Women’s Day, Psychedelic Health takes a look at just some of the women who are spearheading the psychedelic renaissance in the UK.
Psychedelic-assisted psychotherapy is being investigated by Novamind to help people with difficult-to-treat indications and who are historically underserved.
Findings from a study comparing the acute effects of the two compounds suggest that 20 mg psilocybin is equivalent to 100 μg LSD, and 30 mg...
Mydecine Innovations has reported a positive pre-investigational new drug (IND) meeting with America’s Food and Drug Administration (FDA) regarding its psychedelic compound for smoking cessation.
PharmaDrug has generated data showing that DMT-analogues could provide a new treatment for primary open angle glaucoma.
A recent study testing the impact of microdosing LSD has suggested the practice has no therapeutic or cognitive effects.
A new collaboration will investigate the efficacy of EVM-101, a first-generation psychedelic treatment, for the treatment of Cancer Related Distress (CRD).
A new narrative review of systematic evidence has been published by leading researchers at Drug Science to get the facts on the adverse effects of classic...
An amanita muscaria extract – AME-1 – has been shown to hold anti-inflammatory properties in a Psyched Wellness study.